Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
A director of Precigen, Inc. reported selling 235,467 shares of common stock on 12/12/2025. The shares were sold at a weighted average price of $3.6349, with individual trades executed at prices ranging from $3.5000 to $3.7100.
Following these sales, the director beneficially owns 110,603 shares of Precigen common stock in direct ownership. The filing notes that full details of the number of shares sold at each price within the stated range are available upon request.
Precigen, Inc. (PGEN)Randal J. Kirk on a Form 4. Through entity Kapital Joe, he sold 1,086,153 shares of common stock on 11/19/2025 at a weighted average price of $4.47, 942,832 shares on 11/20/2025 at a weighted average price of $4.08, and 937,308 shares on 11/21/2025 at $3.83.
The filing notes that the first two prices are weighted averages for multiple trades within reported price ranges, and Kirk undertakes to provide full trade details on request. After these sales, he continues to report large indirect beneficial ownership positions in Precigen through multiple entities, including 7,434,384 shares held by Kapital Joe and 82,164,767 shares held by R.J. Kirk Declaration of Trust, along with additional holdings through various family and investment vehicles.
Precigen (PGEN) filed its Q3 2025 report highlighting a transition to commercialization after the FDA granted full approval in August for Papzimeos (zopapogene imadenovec) to treat recurrent respiratory papillomatosis. Q3 revenue was $2.9M, led by $1.8M of collaboration and licensing revenue recognized upon terminating a legacy PTC/Agilis agreement, with product and service revenue totaling $1.1M.
Operating expenses rose with launch preparation, including SG&A of $24.0M. The company reported a Q3 net loss of $146.3M, primarily driven by a non‑cash $111.5M loss from the change in fair value of warrant liabilities; a $179.0M deemed dividend on preferred stock increased the net loss attributable to common shareholders to $325.3M. Cash, cash equivalents and investments were $123.6M as of September 30, 2025, aided by a new $100.0M five‑year senior secured term loan to support the Papzimeos launch. Inventory of $3.1M was capitalized following approval. Common shares outstanding were 353,810,556 as of September 30, 2025.
Precigen, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The press release, dated November 13, 2025, is included as Exhibit 99.1 and relates to the company’s results of operations and financial condition for that quarter. The company notes that this information, including the exhibit, is being furnished rather than filed, which affects how it is treated under securities laws.
PRECIGEN, Inc. (PGEN) Form 4: Director Jeffrey B. Kindler reported two separate sales of company common stock. On 09/29/2025 he sold 67,523 shares at a weighted-average price of $3.60, and on 09/30/2025 he sold 106,837 shares at a weighted-average price of $3.38. Following the 09/29/2025 sale his beneficial ownership in the reported class was 452,907 shares (direct). Following the 09/30/2025 sale his beneficial ownership was 346,070 shares (direct). The form includes explanatory footnotes that the reported prices are weighted averages across multiple transactions and that the filer will provide details on request. The Form 4 is signed by Jeffrey B. Kindler by attorney-in-fact Donald P. Lehr.
Precigen, Inc. reported a Form 144 notice for the proposed sale of 106,837 shares of its common stock, with an aggregate market value of $351,493.73, to be sold through Goldman Sachs & Co. LLC on or about 09/30/2025. The shares were acquired as restricted stock units on 03/09/2024 and were granted as compensation.
The filing also discloses a recent sale by the same person: 67,523 shares were sold on 09/29/2025 for gross proceeds of $241,104.38. The filer represents that they are not aware of any undisclosed material adverse information about the issuer.
Rutul R. Shah, Chief Operating Officer and director of Precigen, Inc. (PGEN), reported a purchase of 2,000 shares of Precigen common stock on 09/26/2025 at a reported price of $3.40 per share. After this transaction the reporting person beneficially owned 405,959 shares. The Form 4 was signed on behalf of Mr. Shah by an attorney-in-fact on 09/30/2025. The filing indicates the form was submitted by one reporting person and does not disclose any derivative transactions or additional changes to ownership beyond the common stock purchase.
Phil Tennant, Chief Commercial Officer of Precigen, Inc. (PGEN), reported an insider purchase. On 09/29/2025 he acquired 6,000 shares of Precigen common stock at $3.58 per share. Following the transaction he beneficially owned 65,031 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact.
PRECIGEN, Inc. (PGEN) Form 144 notice shows a proposed sale of 67,523 shares of Common Stock through Goldman Sachs & Co. LLC on 09/29/2025 for an aggregate market value of $245,108.49. The filing states there are 352,910,331 shares outstanding, so the proposed sale represents approximately 0.019% of outstanding shares.
The shares were acquired as restricted stock awards or restricted stock units from the issuer between 03/23/2019 and 03/25/2021, in tranches of 7,911; 24,703; 34,328; and 581 shares. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider purchases by Precigen CFO increased his stake in the company. Harry Thomasian Jr. acquired 8,284 shares on 09/25/2025 at a weighted average price of $3.62 and 2,932 shares on 09/26/2025 at $3.42, bringing his total beneficial ownership to 468,626 shares. The filing shows the transactions were reported on Form 4 and the price for the 09/25 purchases is a weighted average of trades between $3.53 and $3.67. The report was signed on 09/26/2025 by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
